44,315 Shares in Hologic, Inc. (HOLX) Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 44,315 shares of the medical equipment provider’s stock, valued at approximately $2,011,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its position in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock worth $48,100,000 after buying an additional 738,215 shares during the period. Earnest Partners LLC increased its position in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock worth $8,734,000 after buying an additional 205,138 shares during the period. Teachers Advisors LLC increased its position in Hologic by 36.4% in the first quarter. Teachers Advisors LLC now owns 877,549 shares of the medical equipment provider’s stock worth $37,340,000 after buying an additional 234,002 shares during the period. ING Groep NV increased its position in Hologic by 0.7% in the second quarter. ING Groep NV now owns 60,750 shares of the medical equipment provider’s stock worth $2,757,000 after buying an additional 406 shares during the period. Finally, FineMark National Bank & Trust increased its position in Hologic by 3.6% in the second quarter. FineMark National Bank & Trust now owns 62,410 shares of the medical equipment provider’s stock worth $2,832,000 after buying an additional 2,140 shares during the period. 94.43% of the stock is owned by hedge funds and other institutional investors.

Hologic, Inc. (HOLX) opened at 37.95 on Friday. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The company has a market cap of $10.64 billion, a PE ratio of 14.13 and a beta of 0.90. The firm’s 50-day moving average price is $42.85 and its 200 day moving average price is $42.84.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.51 EPS. On average, equities analysts predict that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “44,315 Shares in Hologic, Inc. (HOLX) Acquired by Teacher Retirement System of Texas” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/18/44315-shares-in-hologic-inc-holx-acquired-by-teacher-retirement-system-of-texas.html.

HOLX has been the subject of a number of recent research reports. Royal Bank Of Canada reduced their price target on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Thursday, August 3rd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $53.00 price target on shares of Hologic in a research report on Tuesday, May 9th. Finally, Barclays PLC reduced their price target on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $48.64.

In related news, Director Elaine Ullian sold 6,902 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the sale, the director now owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence M. Levy sold 2,960 shares of the stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $44.54, for a total value of $131,838.40. Following the sale, the director now directly owns 45,634 shares in the company, valued at approximately $2,032,538.36. The disclosure for this sale can be found here. Insiders have sold a total of 51,551 shares of company stock worth $2,244,458 in the last three months. 0.79% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit